SCHEMBL16496003

SCHEMBL16496003

COc1cccc2c1C(O)CC1(CCN(C(=O)OCc3ccccc3)CC1)O2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 0.49
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CYP2C19 P33261 1/20 0.42
SCN5A Q14524 1/20 0.42
SCN9A Q15858 1/20 0.42
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
ENPP2 Q13822 1/20 0.41
ATXN2 Q99700 1/20 0.41
ALOX15 P16050 2/20 0.41
GAA P10253 1/20 0.41
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495736 0.92 IDO1 (0.47) IDO1KMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL16496610 0.88 KMT2A (0.47) IDO1KMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL12481609 0.85 MEN1 (0.50) IDO1KMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL12695175 0.85 MEN1 (0.50) IDO1KMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL3706726 0.82 HDAC3 (0.52) KMT2AMEN1
SCHEMBL16496337 0.81 ACACB (0.56) KMT2ANPSR1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL12481960 0.76 IDO1 (0.47) IDO1KMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL12481142 0.74 TRPM8 (0.59) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL11362432 0.73 OPRM1 (0.48) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL467592 0.72 SIGMAR1 (0.64) KMT2AMEN1NPSR1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9168248-B2 Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase MERCK CANADA INC. (CA) 2015-10-27 US disclosed
EP-2398809-B1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK CANADA INC (CA) 2015-07-08 EP disclosed
US-20110312952-A1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK CANADA INC. 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312952-A1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, SREBF1 IDO1 1403/4885KMT2A 4207/4885MEN1 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.